Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Kimberly-Clark (NYSE:KMB) from Buy to Hold.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

After a turbulent year, things should calm for payers with the advent of a business-friendly Trump administration — though challenges will persist. Here are experts’ biggest predictions for 2025.

As previously reported, TD Cowen upgraded McCormick (MKC) to Buy from Hold with a price target of $90, up from $86. The firm views McCormick’s ...

TD Cowen analyst Andrew Sherman initiated coverage of Axon (AXON) with a Buy rating and $700 price target Axon has built an ecosystem for ...

AI researchers and data scientists. Nvidia announced Project DIGITS — a desktop AI supercomputer with the company’s latest ...

Rate hike expectations +30bps sequentially, though still below survey average. Biz growth & confidence stepped up ...

The surprise departure of Federal Reserve vice chair for supervision Michael Barr is focusing new attention on Michelle ...